---
title: "Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287274170.md"
description: "Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News"
datetime: "2026-05-21T13:15:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287274170.md)
  - [en](https://longbridge.com/en/news/287274170.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287274170.md)
generator: "portal-rs"
---

# Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations | BDTX Stock News

### Related Stocks

- [BDTX.US](https://longbridge.com/en/quote/BDTX.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path](https://longbridge.com/en/news/288927469.md)
- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)
- [Black Diamond Therapeutics Q2 net loss narrows year over year](https://longbridge.com/en/news/295007104.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**